Jump to content

Timothy J. Yeatman

Add links
From Wikipedia, the free encyclopedia
Dr. Timothy Yeatman

Timothy Joseph Yeatman, M.D. F.A.C.S. (born June 10, 1958) is currently the Associate Center Director for Translational Research and Innovation for the Tampa General Hospital Cancer Institute and Professor of Surgery at the University of South Florida, United States. He previously served as the Executive Medical Director of Oncologic Services and the Senior Medical Director for the Oncology Clinical Program at Intermountain Healthcare, serving 23 hospitals and >6000 patients across the State of Utah and beyond. He was also Professor of Surgery at the University of Utah and a Member of the Huntsman Cancer Institute's Cellular Response and Regulation Program. Dr Yeatman was also the Director of Gibbs Cancer Center and President of Gibbs Cancer Center & Research Institute in Spartanburg, South Carolina where he founded the Guardian Research Network, a novel approach to clinical data analytics, leveraging the entire EHR for real time database queries for identifying clinical trial candidates.[1] Yeatman held numerous positions at the Moffitt Cancer Center (MCC) in Florida over a 20 year span from 1992 - 2012. Yeatman served as the Associate Center Director for Clinical Investigations, the Associate Center Director for Translational Research, the Executive Vice President for Translational Research, Professor of Surgery and Cncologic Sciences, and the GI Tumor Program Leader at the Moffitt Cancer Center and the University of South Florida.[2] There he led a $100m Moffitt:Merck collaboration and co-founded a novel biotech company, M2Gen. He also served as Chief Scientific Officer for the Center for Advancement of Science in Space (CASIS), a non-profit organization appointed by Congress and funded by NASA to oversee all scientific use of the International Space Station.[3] He has been funded by the National Cancer Institute (NCI) since 1993 and continues to perform basic and translational colorectal cancer research in genomics and biomarker development.

Background

[edit]

Yeatman was born in Cheverly, Maryland. He received his undergraduate degree at Duke University, where he graduated summa cum laude and Phi Beta Kappa. He received his medical degree from Emory University and completed his surgical internship and residency at the University of Florida, and then a surgical oncology fellowship at MD Anderson Cancer Center, prior to arriving at Moffitt Cancer Center.[2]

Career and research

[edit]

Yeatman has been continuously funded by the National Cancer Institute (NCI) since 1993.[4] He spent 20 years at the Moffitt Cancer Center as a physician scientist, with a clinical and research focus on the problems linked to colorectal cancer. He has spent more than 10 years in the field of molecular profiling and gene expression classifier development, working in the environment of team science and multidisciplinary collaboration. Yeatman has active and completed grants funded by NCI as well as the state of Florida. Yeatman holds numerous patents that include the identification of the first human mutations in the SRC oncogene (Patent Number 7803909)[5] and methods for matching patients to clinical trials using a molecular database (Patent Numbers 8175896, 8095389, 20110288890, 20080033658).[5][6]

Yeatman is a pioneer in personalized medicine, having headed the development of the world's largest human tumor bio-repository and database with comprehensive molecular profiling of approximately 20,000 tumor specimens. He was the principal architect of the Total Cancer Care (TCC) initiative in personalized medicine, and served as the president and founding chief scientific officer of M2Gen (a wholly owned subsidiary of the MCC that implemented and managed the TCC project).[7] He participated in recruiting a nationwide network of 18 hospitals (TCC Consortium) that collected, macrodissected, curated and profiled more than 20,000 snap frozen tumor samples on a single Affymetrix platform with a commercial pipeline. Yeatman also served as chair of the Joint Scientific Committee, and the co-chair of the Joint Operating Committee, which made him the primary liaison with Merck & Co. in developing and managing the more than $150 million project and the derivative science.[8]

Awards and recognition

[edit]

Yeatman has received numerous honors and awards including the James IV Association of Surgeons Traveling Fellowship, Europe;[9] the Center Director's Award for Outstanding Research at Moffitt Cancer Center;[2] and the James Ewing Foundation Trainee Award, Society of Surgical Oncology, and the Million Dollar Researcher award at the University of South Florida.[10] Yeatman has been continuously funded through additional grants from the American Cancer Society, including a Director's Challenge Award for the global profiling of human colon cancer.[2] He is a member of numerous societies including the American Surgical Association and the Society of Surgical Oncology and the American Association for Cancer Research. He has published around 150 articles in the top peer-reviewed journals in his field,[11] including the prestigious Science,[12] Nature Genetics,[13] Nature Medicine,[14] Nature Reviews Cancer,[15] as well as the Journal of the National Cancer Institute,[16][17] and Cancer Research,.[18][19][20][21]

References

[edit]
  1. ^ "Meet Our Leadership | Gibbs Cancer Center | Spartanburg, SC | Gibbs Cancer Center". Archived from the original on 2013-10-16. Retrieved 2013-10-16.
  2. ^ a b c d "Timothy Joseph Yeatman, MD". Archived from the original on 2013-10-17. Retrieved 2024-06-29.
  3. ^ "CASIS Names Dr. Timothy J. Yeatman Interim Chief Scientist - CASIS - Center for the Advancement of Science in Space". Archived from the original on 2013-10-21. Retrieved 2013-10-16.
  4. ^ "RePORT ⟩ RePORTER".
  5. ^ a b "Patentfish.com Search (dead)". Archived from the original on 2011-08-27. Retrieved 2013-10-16.
  6. ^ "Timothy Yeatman Inventions, Patents and Patent Applications - Justia Patents Search".
  7. ^ "Moffitt promotes Timothy Yeatman to M2Gen chief science officer - Tampa Bay Business Journal". Archived from the original on 2010-09-26.
  8. ^ "Moffitt, Merck break ground on collaborative project - Tampa Bay Business Journal". Archived from the original on 2007-11-17.
  9. ^ "James IV Association of Surgeons | Members".
  10. ^ "Stocks". 17 October 2023.[dead link]
  11. ^ "Dr. Timothy J. Yeatman" (PDF). Archived from the original (PDF) on 2013-10-17. Retrieved 2013-10-16.
  12. ^ Attallah AM, Yeatman TJ, Noguchi PD, Johnson JB. Antibody-dependent cell-mediated cytotoxicity: detection by automated flow cytometry with ultramicro techniques. Science. 1980 Jul 18;209(4454):404-6. PMID 7384812.
  13. ^ Irby RB, Mao W, Coppola D, Kang J, Loubeau JM, Trudeau W, Karl R, Fujita DJ, Jove R, Yeatman TJ. Activating SRC mutation in a subset of advanced human colon cancers. Nature Genetics. 1999 Feb;21(2):187-90. PMID 9988270.
  14. ^ Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, Chang AC, Zhu CQ, Strumpf D, Hanash S, Shepherd FA, Ding K, Seymour L, Naoki K, Pennell N, Weir B, Verhaak R, Ladd-Acosta C, Golub T, Gruidl M, Sharma A, Szoke J, Zakowski M, Rusch V, Kris M, Viale A, Motoi N, Travis W, Conley B, Seshan VE, Meyerson M, Kuick R, Dobbin KK, Lively T, Jacobson JW, Beer DG. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine. 2008 Aug;14(8):822-7. PMID 18641660.
  15. ^ Yeatman TJ. A renaissance for SRC. Nature Reviews Cancer. 2004 Jun;4(6):470-80. Review. PMID 15170449.
  16. ^ Chen DT, Hsu YL, Fulp WJ, Coppola D, Haura EB, Yeatman TJ, Cress WD. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. Journal of the National Cancer Institute. 2011 Dec 21;103(24):1859-70. PMID 22157961.
  17. ^ Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. Journal of the National Cancer Institute. 2002 Apr 3;94(7):513-21. PMID 11929952.
  18. ^ Hegde P, Qi R, Gaspard R, Abernathy K, Dharap S, Earle-Hughes J, Gay C, Nwokekeh NU, Chen T, Saeed AI, Sharov V, Lee NH, Yeatman TJ, Quackenbush J. Identification of tumor markers in models of human colorectal cancer using a 19,200-element complementary DNA microarray. Cancer Research. 2001 Nov 1;61(21):7792-7. PMID 11691794.
  19. ^ Irby RB, Yeatman TJ. Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Research. 2002 May 1;62(9):2669-74. PMID 11980666.
  20. ^ Chen T, Yang I, Irby R, Shain KH, Wang HG, Quackenbush J, Coppola D, Cheng JQ, Yeatman TJ. Regulation of caspase expression and apoptosis by adenomatous polyposis coli. Cancer Research. 2003 Aug 1;63(15):4368-74. PMID 12907606.
  21. ^ Irby RB, Malek RL, Bloom G, Tsai J, Letwin N, Frank BC, Verratti K, Yeatman TJ, Lee NH. Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype. Cancer Research. 2005 Mar 1;65(5):1814-21. PMID 15753379.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Timothy_J._Yeatman&oldid=1246645296"